A German Study Evaluating the Efficacy and the Benefit of Integrated Personalized Diabetes Management (PDM) for Type 2 Diabetes Patients. (PDM-ProValueGP)

This is an interventional diagnostic trial for Diabetes Mellitus, Type 2 Read More

Inclusion Criteria:

• Existence of a signed Informed Consent form (before any study procedure)
• Diagnosed Type 2 diabetes mellitus
• Age =18 years
• Insulin therapy for =6 months: BOT, SIT, CT or ICT
• HbA1c =7.5% within the last 6 weeks before study visit 1 (patient's inclusion)
• Longer-term diabetes care by the trial site (at least for the duration of the 12-month study participation)
• General practitioner is the primary practitioner in the diabetes care of the patient
• Insured by the statutory health insurance (GKV) as a statutory or voluntarily insured member or as a family co-insured member
• Willing and able to participate in the study and to follow the study procedures, among other things sufficient command of the German language, spoken and written

Exclusion Criteria:

• Diabetes treatment by insulin pump therapy (CSII)
• Experience with the use of special software for systematic processing of SMBG data, e.g. the Accu-Chek® Smart Pix System/Software, the Accu-Chek® 360° Software and/or the Diabetes Software DIABASS
• Presence of terminal renal failure / dialysis and/or a loss of sight or a tumor illness
• Chronic use of steroids in adrenal suppressant doses, of other immuno-modulatory drugs or chemotherapy
• Known alcohol, drug and medication abuse
• Known metabolic disorders and/or disorders or therapies that could lead to or have led to wrong measured results (e.g. with the blood glucose measurement)
• Existing pregnancy, breast-feeding or plan to become pregnant during study participation
• Physical illness and/or psychological disorder with the result that the patient cannot implement the medical treatment recommendations independently
• Dependency relationship to the sponsor or to the investigator, e.g. as a professional colleague or family member